Former chief financial officer of Myriad Genetics, Jay Moyes, has been appointed to the board of directors at Integrated Diagnostics. After his tenure at Myriad, Moyes served as chief financial officer of XDx, a molecular diagnostic company. Currently, he is director and chair of the audit committees of both Osiris Therapeutics and BioCardia.
Former vice president of sales at Myriad, Mark Willig, has been named executive vice president of North American sales at Agendia. Willig has held a number of leadership positions within the healthcare industry, including general manager and chief commercial officer at Exiqon, vice president of global sales for Thermo Fisher's anatomic pathology business unit, executive vice president of sales and marketing at Specialty Labs, as well as 12 years in commercial roles at Abbott Diagnostics. He holds a BS from the University of Missouri.